Linagliptin Zentiva

Linagliptin, the active ingredient in Linagliptin Zentiva, is a DPP-4 inhibitor presented as a tablet for oral use. It helps lower blood glucose levels in adults with type 2 diabetes mellitus. GNH USA supplies Linagliptin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP-4 inhibitor used to improve glycaemic control in type 2 diabetes. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when combined with metformin, sulfonylureas or insulin. - Type 2 diabetes mellitus (renal impairment): provides effective glucose control without dose adjustment in patients with reduced kidney function.

Adverse reactions reported with linagliptin are generally mild to moderate.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory infection symptoms. - Headache: transient cranial discomfort. - Upper respiratory tract infection: cough, sore throat. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain. - Back pain: musculoskeletal aches.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypoglycaemia: when combined with insulin or sulfonylureas. - Acute kidney injury: rare reports of renal function decline.

Linagliptin should be used with clinical monitoring and patient education. - Renal impairment: no dose adjustment needed, but monitor renal function periodically. - Hepatic impairment: use with caution; assess liver enzymes before initiation. - Pregnancy: safety not established; prescribe only if potential benefit justifies the risk. - Breastfeeding: insufficient data; consider alternative therapy. - Concomitant sulfonylureas or insulin: monitor for signs of hypoglycaemia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines that affect glucose metabolism or drug metabolism pathways.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin effectiveness.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed. - Diuretics (e.g., thiazides): may affect blood glucose control. - Antihypertensive agents: monitor blood pressure as glycaemic changes can influence cardiovascular status.